Annual Report Reveals Going Concern, Ineffective Controls, and Auditor Instability

summarizeSummary

Nika Pharmaceuticals' annual report reveals a going concern warning, ineffective internal controls, and a history of frequent auditor changes, signaling severe financial and operational instability.

check_boxKey Events

• Going Concern Warning Issued

  The company's independent accountants issued a 'going concern' opinion, citing an accumulated deficit of $9,004,009 and a net loss of $76,398 for 2025, raising substantial doubt about its ability to continue operations.

• Internal Controls Deemed Ineffective

  Management concluded that disclosure controls and internal control over financial reporting were ineffective as of December 31, 2025, due to material weaknesses including the lack of an audit committee and insufficient segregation of duties.

• Frequent Auditor Changes in 2024

  The company changed auditors four times in 202 year, dismissing B F Borgers CPA PC, Fruci & Associates II, PLLC (resigned), and OLAYINKA OYEBOLA & CO (terminated before services), before engaging Boladale Lawal & Co.

• Heavy Reliance on Related Party Financing

  Nika Pharmaceuticals is significantly dependent on loans from its CEO and related entities, with $318,624 due to related parties as of December 31, 2025, to fund general operating expenses.

auto_awesomeAnalysis

Nika Pharmaceuticals' annual report for fiscal year 2025 highlights severe financial and operational challenges. The company's independent accountants have issued a 'going concern' opinion, citing an accumulated deficit of over $9 million and a net loss, raising substantial doubt about its ability to continue operations. Furthermore, management concluded that disclosure controls and internal control over financial reporting were ineffective due to material weaknesses, including the absence of an audit committee and lack of segregation of duties. The company also experienced an alarming frequency of auditor changes in 2024, with four different firms engaged or terminated within the year, which is a significant red flag for financial transparency and stability. Operations are heavily reliant on loans from the CEO and related parties, and a previously announced acquisition of a factory building and land, central to their pharmaceutical production plans, was reversed. These factors collectively indicate a company in deep distress with fundamental governance and financial reporting issues, posing extreme risk to investors.